Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07563881
PHASE3

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Sponsor: Rapport Therapeutics Inc.

View on ClinicalTrials.gov

Summary

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

333

Start Date

2026-06-05

Completion Date

2029-09

Last Updated

2026-06-16

Healthy Volunteers

No

Interventions

DRUG

RAP-219

RAP-219 high dose tablets administered orally daily

DRUG

RAP-219

RAP-219 medium dose tablets administered orally daily

OTHER

Placebo

Matching placebo tablets administered orally daily

Locations (3)

Amicis Research Center

Palmdale, California, United States

Indiana University Health Fort Wayne Neurology

Fort Wayne, Indiana, United States

Mid-Atlantic Epilepsy and Sleep Center

Bethesda, Maryland, United States